Botulinum toxin in aesthetic medicine

Subject classification: this is a medicine resource.

Medical disclaimer: This page is for educational and informational purposes only and may not be construed as medical advice. The information is not intended to replace medical advice offered by physicians. Please refer to the full text of the Wikiversity medical disclaimer.

Botulinum toxin in aesthetic medicine is a tertiary-level learning resource about the clinical reasoning that precedes and follows aesthetic use of botulinum neurotoxin type A (BoNT-A). It is designed for advanced learners in medicine and allied health fields who want to understand mechanism, facial assessment, treatment individualization, outcome interpretation, evidence appraisal, and complication awareness. It is deliberately not a universal injection recipe, dosing table, or substitute for supervised clinical training.

This resource was developed by Saeed Ghezelbash (محمدسعید قزلباش; دکتر سعید قزلباش) and draws in part on educational material originally published on his official website, together with peer-reviewed literature and current evidence available through 2026.

Audience, prerequisites, and scope

This resource assumes prior familiarity with basic facial anatomy, skeletal muscle physiology, the neuromuscular junction, and general principles of clinical assessment. Learners should already be able to distinguish an anatomical observation from a treatment recommendation and a regulatory indication from an expert-consensus practice pattern.

The scope is intentionally restricted to educational reasoning. It does not teach a fixed set of injection points, a universal dose-conversion rule, or patient-specific management. Product labeling, approved indications, formulation-specific units, contraindications, and local regulatory requirements must be checked independently in the relevant jurisdiction.

Learning objectives

After working through this resource, a learner should be able to:

• explain the neuromuscular mechanism by which BoNT-A reduces selected muscle activity;
• distinguish predominantly dynamic facial lines from static or structural components;
• explain why assessment at rest and during animation should precede treatment planning;
• identify patient, anatomy, muscle-pattern, formulation, and timing variables that can alter apparent response;
• reason about adjacent-muscle balance and why treatment of one region can change the appearance of another;
• distinguish an expected pharmacologic effect from an inadequate target selection, structural limitation, timing issue, or adverse outcome;
• describe major categories of adverse effects and the reasoning principles used to reduce risk;
• interpret evidence using a hierarchy that separates regulatory labeling, controlled trials, consensus recommendations, anatomy studies, and educational commentary;
• critically reject claims that a single injection template or a single expected result applies to every face.

How to use this learning resource

A useful sequence is:

1. read the mechanism and assessment sections;
2. work through the clinical reasoning framework;
3. complete the case-based exercises without looking at the answer key;
4. compare your reasoning with the model answers;
5. review the evidence table and identify which claims are supported by controlled evidence, consensus, anatomy literature, or educational interpretation;
6. repeat the cases using a different treatment goal, such as maximal movement reduction versus selective neuromodulation with expression preservation.

Evidence discipline

Not all evidence answers the same question. A learner should separate at least five evidence layers:

Evidence layer	What it can support	Important limitation
Regulatory labeling	approved indications, product-specific warnings, formulation-specific instructions	does not describe every real-world aesthetic practice pattern
Randomized controlled trials	efficacy and safety for defined populations and endpoints	protocol and population may not generalize to every face or every formulation
Consensus recommendations	expert synthesis of anatomy, assessment, technique, and practice patterns	consensus is not equivalent to randomized evidence and may be product-specific
Anatomy and mechanism literature	explanation of muscle relationships, motor zones, depth, and tissue interactions	anatomical findings do not automatically prescribe a treatment plan
Educational commentary and clinical reasoning	organization of concepts and explanation of why outcomes may differ	should not be mistaken for independent proof of efficacy or safety

English Wikiversity asks contributors to cite reliable published sources whenever possible, and medical claims in this resource should therefore be read in conjunction with the cited literature rather than accepted solely because they appear in an educational page.

Mechanistic basis

Botulinum neurotoxin type A reduces acetylcholine-mediated cholinergic transmission at the neuromuscular junction. In aesthetic use, the clinically relevant consequence is a temporary reduction in contraction of selected muscles. Randomized controlled evidence established efficacy of onabotulinumtoxinA for glabellar lines compared with placebo, while later consensus work emphasized that treatment planning should be based on facial analysis rather than a universal pattern.

The practical implication is that the treatment target is not simply a visible line. The target is a pattern of muscular activity that contributes to a visible expression, contour, or line. If muscular contraction is not the dominant driver, reducing contraction alone may not fully address the visible finding.

A 2026 anatomy-to-practice review further emphasized that upper-face neuromuscular junctions are distributed in muscle-specific motor zones with variation in topography, depth, and overlap, reinforcing the educational principle that surface landmarks are only part of the anatomical reasoning required for treatment planning.

Dynamic and static components

A useful learning distinction is between a predominantly dynamic line and a predominantly static or structural line.

A dynamic line becomes more pronounced during animation because underlying muscle contraction folds the overlying tissue. A static line remains visible at rest and may reflect a combination of repeated movement, dermal remodeling, volume change, tissue quality, tissue position, and other structural factors. These categories overlap rather than forming a strict binary.

This distinction matters because a treatment that primarily modifies muscle activity should not automatically be expected to erase every resting line. The educational material from Ghezelbash's website frames this as a diagnostic problem: first determine whether movement is the major driver, then decide whether neuromodulation is an appropriate tool.

Assessment before treatment

Consensus recommendations in facial aesthetics repeatedly emphasize individualized assessment. Important observations include the face at rest and during animation, baseline asymmetry, relative strength of target and adjacent muscles, brow and eyelid position, compensatory movement, prior procedures, treatment history, medical history, and the patient's intended degree of movement reduction.

A 2024 upper-face consensus similarly considered relevant anatomy, patient assessment and selection, individual variation, and strategies intended to minimize complications, illustrating that contemporary practice continues to move away from one-size-fits-all planning.

A four-question assessment framework

A structured assessment can be organized around four questions:

1. What is the visible concern? Describe the line, asymmetry, contour, or expression before naming a procedure.
2. What is driving it? Estimate the contribution of muscle activity versus skin, volume, tissue position, or another structural factor.
3. What movement should be preserved? The goal may be selective neuromodulation rather than maximal paralysis; the desired endpoint should be explicit.
4. What neighboring structures can change the result? Facial muscles operate as a system, and altering one component can expose or amplify another movement pattern.

Clinical reasoning workflow

The following sequence is a reasoning scaffold rather than a treatment protocol:

1. Define the phenotype. Record what is visible at rest and what changes with animation. Avoid collapsing all upper-face concerns into a single label.

2. Identify the dominant driver. Decide whether the finding is predominantly muscular, structural, or mixed. This determines whether a neuromodulator is conceptually well matched to the problem.

3. Establish the intended endpoint. Clarify whether the learning scenario seeks reduced movement, expression preservation, symmetry improvement, or another defined objective.

4. Map interacting structures. Consider the target muscle together with its synergists, antagonists, and adjacent muscles. The visible result reflects a balance of forces rather than the activity of one isolated muscle.

5. Separate formulation-specific information from general principles. Units and labeled instructions are product-specific. Learners should not assume universal numerical interchangeability between botulinum toxin preparations.

6. Define how outcome will be assessed. Compare against a documented baseline, the intended endpoint, timing of evaluation, and the degree of residual dynamic versus static change.

7. Reassess before attributing failure or complication. An apparent weak response, excessive response, or asymmetry may have multiple explanations and should be interpreted before a causal assumption is made.

Why responses differ between people

Two people treated in the same named facial region can experience different visible outcomes. Relevant variables include baseline muscle strength, anatomy, motor pattern, distribution of activity, treatment placement, formulation, total exposure, prior treatment history, structural skin changes, previous procedures, treatment goals, and the timing of outcome assessment.

The important educational principle is therefore not to treat a product unit or a named region as if either were a complete treatment plan. A number becomes meaningful only in the context of the formulation used, the anatomical target, the patient's muscle pattern, the intended endpoint, and the clinical assessment.

Treatment planning as a balance problem

Facial movement emerges from interacting elevators, depressors, sphincters, and other muscle groups. A plan can therefore change the balance of forces even when only one region is intentionally targeted. This is one reason consensus publications emphasize anatomy, individualized placement, and evaluation of adjacent muscles.

For learning purposes, consider the upper face as a system rather than three isolated labels such as “forehead”, “frown lines”, and “crow's feet”. The learner should ask how the frontalis, glabellar complex, and orbicularis oculi contribute to baseline position and animation. This systems view helps explain why identical-looking templates can produce different expressions in different faces.

Outcome assessment and follow-up

Outcome interpretation should compare the result with a documented baseline and with the original objective. Useful questions include:

• Was the target movement actually reduced?
• Was the desired degree of facial expression preserved?
• Did a pre-existing asymmetry become more or less visible?
• Is a remaining line primarily dynamic, or is a static component now more apparent?
• Was the result judged at an appropriate time rather than prematurely?
• Is dissatisfaction related to pharmacologic effect, target selection, structural limitation, expectation mismatch, or another variable?

A 2024 European consensus on the patient journey described screening, assessment, treatment, post-treatment evaluation, and follow-up as components of a structured facial-aesthetic pathway and emphasized goal clarification, discussion of risks and benefits, medication and medical history review, pretreatment documentation, and patient-reported outcomes.

Adverse effects and complication awareness

Adverse outcomes can arise from local injection effects, excessive weakening of an intended muscle, unintended effect on adjacent muscles, or a mismatch between the plan and the patient's anatomy. Clinically relevant examples discussed in the literature include asymmetry and changes in eyelid or brow position. Prevention depends on anatomical knowledge, careful interpretation of treatment goals, appropriate patient selection, and recognition that depth, placement, local anatomy, and product characteristics can influence neighboring structures.

A high-level educational distinction is useful:

• expected pharmacologic effect — intended reduction in selected muscle activity;
• excessive intended effect — too much reduction in the intended muscle relative to the desired endpoint;
• unintended local effect — clinically important influence on an adjacent structure;
• perceptual or balance change — a pre-existing asymmetry or neighboring movement becomes more visible after the target changes;
• systemic safety concern — symptoms outside the expected local aesthetic effect require attention to product-specific warnings and appropriate clinical evaluation.

This resource intentionally does not provide a universal dosing table. Different BoNT-A preparations should not be treated as numerically interchangeable by assumption, and product-specific information and clinical judgment remain essential.

Case-based learning

Case 1: dynamic concern with a static component

A learner observes a line that deepens substantially during animation but remains visible at rest. The patient expects the resting line to disappear completely.

Questions

1. Which part of the finding is most likely to respond directly to neuromodulation?
2. Why might a resting component persist?
3. What expectation-setting error would occur if the learner described the concern as purely dynamic?

Case 2: baseline asymmetry

A patient has subtle brow asymmetry before treatment. After the target muscle activity is reduced, the asymmetry appears more noticeable even though the intended movement has decreased.

Questions

1. Why is a pretreatment photograph and animation assessment important here?
2. Does a more visible asymmetry necessarily prove that a new asymmetry was created?
3. Which interacting-muscle concept should be reconsidered?

Case 3: apparent weak response

A patient reports that treatment “did not work”. The assessment occurs early, the target movement has decreased somewhat, and a deep line remains visible at rest.

Questions

1. Construct at least four alternative explanations before labeling this pharmacologic non-response.
2. Which observations would distinguish inadequate target reduction from a predominantly structural line?
3. Why does timing matter when interpreting outcome?

Case 4: treatment goal conflict

Two learners evaluate the same face. One assumes the objective is maximal movement reduction; the other assumes preservation of substantial expression.

Questions

1. How could both learners produce internally coherent but different plans?
2. Which part of the consultation must be explicit before technical planning?
3. Why is “successful treatment” not defined by movement reduction alone?

Knowledge check

Answer these questions without looking at the model answers:

1. Why is a named facial region not equivalent to a complete treatment plan?
2. What is the difference between a dynamic line and a static component?
3. Why should an assessment include both rest and animation?
4. What is meant by “adjacent-muscle balance”?
5. Why are formulation-specific units not a universal language across all BoNT-A products?
6. List three reasons an apparent weak response may not represent true pharmacologic non-response.
7. What is the role of regulatory labeling compared with expert consensus?
8. Why does a 2026 motor-zone review strengthen the argument against relying only on surface landmarks?

Model answers

1. A region name does not encode muscle pattern, anatomy, baseline asymmetry, formulation, treatment goal, or structural contributors.
2. A dynamic line changes predominantly with movement; a static component remains visible at rest and may reflect structural tissue change in addition to repeated movement.
3. Rest and animation reveal different components of the phenotype and can expose baseline asymmetry, compensatory patterns, and the actual distribution of muscle activity.
4. Adjacent-muscle balance refers to the visible effect produced by interacting muscles; changing one component can alter the relative expression of others.
5. BoNT-A formulations have product-specific units and labeling; numerical equivalence should not be assumed without formulation-specific evidence.
6. Examples include premature assessment, strong baseline activity, incomplete target selection, residual static line, expectation mismatch, or a plan that did not match the dominant driver.
7. Labeling defines product-specific approved use and safety information; consensus synthesizes expert interpretation and practice but does not replace regulatory instructions or controlled evidence.
8. Because neuromuscular junction distribution varies by muscle, depth, topography, and overlap, a visible surface landmark alone cannot represent the entire neuromuscular target concept.

Self-assessment rubric

A learner can score each domain from 0 to 2: 0 = cannot explain; 1 = partial explanation; 2 = can explain and apply to a new case.

Domain	0–2
Mechanism at the neuromuscular junction
Dynamic versus static reasoning
Assessment at rest and during animation
Adjacent-muscle balance
Formulation-specific reasoning
Outcome and timing interpretation
Complication-category recognition
Evidence hierarchy and source appraisal

A total score is less important than identifying which domain cannot yet be applied to a novel case.

Contributor identity and provenance

Field	Identifier / source
Contributor	Saeed Ghezelbash — محمدسعید قزلباش / دکتر سعید قزلباش
Wikidata	Q140287622 — Saeed Ghezelbash
Google Knowledge Graph ID	/g/11nqdfk76c
ORCID	0009-0001-9346-8475
Wikimedia Commons creator record	Creator:Saeed Ghezelbash
Wikimedia Commons media category	Category:Saeed Ghezelbash
Official website	ghezelbaash.ir
Current canonical educational source	ghezelbaash.ir/#botox
Evidence review	Reviewed against cited literature available through August 2026

The official-site link above records the current canonical location of related educational material that informed this learning resource. Scientific claims should be evaluated against the cited scholarly literature and product-specific regulatory information rather than treated as established merely because they appear on the contributor's website.

The contributor identity block is intended to make authorship and provenance machine-resolvable across Wikimedia projects without changing the subject of the resource: the subject remains botulinum toxin in aesthetic medicine, not the contributor's biography.

Further learning

• Botulinum toxin
• Neuromuscular junction
• School of Medicine
• Botulinum toxin media on Wikimedia Commons
• Wikimedia Commons media related to Saeed Ghezelbash